Aminah Abdul Razzack

Aminah Abdul Razzack

Auto-generated profile, based on publicly available information

Aminah Abdul Razzack

Dr. N.T.R University of Health Sciences, Vijawayada, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
PDF file
ASAzza Sarfraz
Azza Sarfraz
Zouina SarfrazZouina Sarfraz
Zouina Sarfraz
ARAminah Abdul Razzack
Aminah Abdul Razzack
GPGaurav Patel
Gaurav Patel
MSMuzna Sarfraz
Muzna Sarfraz
The novel coronavirus disease 2019 (COVID-19) predisposes patients to venous thromboembolism (VTE) due to risk factors, severe infection, and severe inflammatory responses. The objective is to determine the risk of developing VTE after corticosteroid administration during COVID-19 treatment. Using PRISMA reporting guidelines, a review was conducted from inception until 20 September 2020 with MESH terms including “venous thromboembolism” and “covid-19,” using MEDLINE, Scopus, CINAHL Plus, and WHO Global Database. The inclusion criteria included studies with COVID-19 patients aged 18 years and older with VTE diagnosed by duplex ultrasonography or computed tomography pulmonary angiography (CTPA). Exclusion criteria were studies with non COVID-19 patients and non-VTE patients aged less than 18 years. Quality appraisal was conducted of included studies using the Newcastle-Ottawa Scale (NOS). A random-effect model using 95% confidence intervals, and significance of findings was assessed using Review Manager V5.4.We included 12 observational studies with 2801 patients (VTE n = 434; non-VTE; n = 2367). Patients had a higher risk of presenting with VTE when being administered corticosteroids during treatment of COVID-19 (RR = 1.39, 95% CI = 1.10 to 1.77, I2 = 0%). A positive effect size was found (SMD = 1.00, 95% CI = 0.67 to 1.32, I2 = 85%) for D-dimer laboratory values (µg/mL) in the VTE group. While critically ill COVID-19 patients are more likely to require corticosteroid treatment, it may be associated with increased risk of VTE, and poor clinical prognosis. Risk assessment is warranted to further evaluate patients as case-by-case in reducing VTE and worsening clinical outcomes.

1 January 2021 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
JSJuan Pablo Sosa
Juan Pablo Sosa
MCMaria Mercedes Ferreira Caceres
Maria Mercedes Ferreira Caceres
JCJennifer Ross Comptis
Jennifer Ross Comptis
JQJorge Quiros
Jorge Quiros
FPFortunato S Príncipe-Meneses
Fortunato S Príncipe-Meneses
SMSheeba Marian
Sheeba Marian
Sosa JP, et al. Infect Chemother. 2021 Jun;53(2):247-260. https://doi.org/10.3947/ic.2021.0028

13 November 2020 in Cureus
Verified
Journal Article
Open access
PDF file
RPRakesh Pilla
Rakesh Pilla
SPSUJITH KUMAR PALLETI
SUJITH KUMAR PALLETI
RRRenuka Rayala
Renuka Rayala
SSSatish Reddy Skss
Satish Reddy Skss
ARAminah Abdul Razzack
Aminah Abdul Razzack
SKSruti Kalla
Sruti Kalla
Diabetes is prevalent in the Indian population, to the extent that the diabetes burden matches that of nutritional anemia. We aimed to determine the effects of iron and vitamin B12 deficiency anemia on glycated haemoglobin (HbA1c) concentrations in individuals without diabetes. The study comprises 100 patients with iron deficiency anemia, 100 with vitamin B12 deficiency anemia, and 100 healthy volunteers as a control group. Each of the first two groups was subdivided into two groups depending on the severity of anemia based on Hb levels. We treated with iron replenishment in the iron deficiency group and B12 replenishment in the B12 deficiency group for three months. We noted HbA1c levels before and after the therapy. Data were entered into the SPSS package. For comparing pre and post-therapy levels, we used the Paired 't' test. The mean HbA1c before treatment were 6.1% ± 0.23% and 5.5% ± 0.24%, and the values after treatment were 5.1% ± 0.14% and 4.6% ± 0.2% in severe iron deficiency anemia subgroup and mild to moderate subgroup, respectively. The mean HbA1c in the iron-deficiency anemia control group was 5.2% ± 0.2%. The mean HbA1c levels before treatment were 5.9% ± 0.3% and 5.6% ± 0.19%, and after treatment were 5.0% ± 0.15% and 4.9% ± 0.16% in severe and mild to moderate B12 deficiency anemia, respectively. The mean HbA1c in the vitamin B12 deficiency anemia control group was 5.1% ± 0.2%. HbA1c in both types of anemia subjects showed a significant decrease with appropriate therapy. Physicians should consider rechecking patient haemoglobin values and correcting a patient's anemia before determining the patient's glycemic status using HbA1c to avoid misinterpretation of their diabetes status.

20 October 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
YSyasar sattar
yasar sattar
ARAminah Abdul Razzack
Aminah Abdul Razzack
RKRitika Kompella
Ritika Kompella
NANoora Alhajri
Noora Alhajri
JAJunaid Arshad
Junaid Arshad
MAM. Chadi Alraies
M. Chadi Alraies

1 January 2021 in Infection & Chemotherapy
Verified
Journal Article
Open access
ARAminah Abdul Razzack
Aminah Abdul Razzack
SHSyed Adeel Hassan
Syed Adeel Hassan
SPSai Kumar Reddy Pasya
Sai Kumar Reddy Pasya
GEGreeshma Erasani
Greeshma Erasani
SKSham Kumar
Sham Kumar
SRSarah Abdul Razzack
Sarah Abdul Razzack
Razzack AA, et al. Infect Chemother. 2021 Aug;53:e46. https://doi.org/10.3947/ic.2021.0060

24 March 2023
Verified
Book Chapter
Closed access
ARAminah Abdul Razzack
Aminah Abdul Razzack
NPNirmit Patel
Nirmit Patel
APAneri Patel
Aneri Patel